期刊文献+

RNA干扰抑制ERCC1对非小细胞肺癌化疗敏感性的影响 被引量:3

The effect of RNA interference-mediated ERCC1 gene on the chemo-treatment sensitivity of non-small-cell lung cancer
下载PDF
导出
摘要 目的探讨利用RNA干扰技术沉默切除修复交叉互补基因组1(ERCC1)表达对非小细胞肺癌耐药细胞株顺铂化疗敏感性的影响。方法设计并合成3段靶向人的ERCC1基因的小分子干扰RNA(siRNA),构建携带ERCC1-shRNA的重组质粒表达载体,采用脂质体Lipofectamine 2000转染入人肺癌细胞株A549/DDP,荧光镜下观察并测定转染效率;应用逆转录聚合酶链反应(RT-PCR)检测转染前后ERCC1mRNA的表达情况;应用四甲基偶氮唑蓝比色法(MTT)检测干扰ERCC1后A549/DDP细胞对顺铂敏感性的变化。结果转染针对ERCC1的siRNA后,转染组A549/DDP细胞内ERCC1mRNA表达均下降,转染后肺癌A549/DDP细胞对顺铂敏感性增加。结论利用RNA干扰技术能够筛选出高效的特异阻断ERCC1基因表达的siRNA;ERCC1基因表达下调能够增加肺癌A549/DDP细胞对顺铂的敏感性,部分逆转耐药。 Objective To investigate changes of platinum-based chemotherapy sensitivity of silencing excision repair cross complementation 1(ERCC1) gene expression by using RNA interference in non-small-cell lung cancer(NSCLC)drug resistance cell lines.Methods Three siRNA sequences targeting ERCC1 gene were designed and synthesized.Recombinant plasmid expression vector which carrying ERCC1-shRNA was constructed and transfected into A549/DDP cells with Lipofectamine 2000.Transfection efficiency was measured in the fluorescent microscope.The expression of ERCC1 mRNA was detected by reverse transcription-polymerase chain reaction(RT-PCR).The change of cisplatin sensitivity after interference was test by MTT assay.Results After transfection of ERCC1-siRNA,the ERCC1 mRNA expressions in A549/DDP cells were all reduced.The sensitivity to cisplatin of A549/DDP cell line was increased after transfection.The sensitivity to cisplatin of A549/DDP cell line was increased after transfection.Conclusion Highly effective and specific siRNA targeting ERCC1 gene can be successfully screened by RNA interference technique.Selective silencing of ERCC1 gene promotes the sensitivity to cisplatin in A549/DDP cell and can partly reverse the cisplatin resistance in human cisplatin resistant lung adeno-carcinoma cell lines A549/DDP in vitro.
作者 宋志雨 周航
出处 《重庆医学》 CAS CSCD 北大核心 2011年第32期3232-3235,I0001,共5页 Chongqing medicine
基金 贵州省科技厅资助项目[黔科合J字(2007)2129]
关键词 RNA干扰 非小细胞肺癌 顺铂 切除修复交叉互补基因组1 A549/DDP细胞 RNA interference carcinoma non-small-cell lung cisplatin excision repair cross complementation 1 gene A549/DDP cells
  • 相关文献

参考文献20

  • 1Herbst RS,Dang NH,Skarin AT.Chemotherapy for ad-vanced non-small cell lung cancer. Hematology Oncology Clinics of North America . 1997
  • 2Joshi MB,Shirota Y,Danerberg KD,et al.High gene ex-pression of TS1,GSTP1and ERCC1are risk factors forsurvival in patients treated with trimodality therapy foresophageal cancer. Clinical Cancer Research . 2005
  • 3Livak KJ,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods . 2001
  • 4Jansen B,Zangemeister-Wittke U.Antisense therapy for cancer-the time of truth. Lancet Oncology,The . 2002
  • 5Furuta T,Ueda T,Aune G. et al.Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Research . 2002
  • 6Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science . 2004
  • 7Bernstein C,Bernstein H,Payne C M,et al.DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutation Research . 2002
  • 8Sakamoto M,Kondo A,Kawasaki K,et al.Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Human Cell . 2001
  • 9Mansouri A,Zhang Q,Ridgway L D,et al.Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncology Research . 2003
  • 10Katano K,Kondo A,Safaei R,et al.Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research . 2002

同被引文献42

  • 1Ettinger D, Akerley W, Bepler G, et a1. Non-small cell lung cancer. J Natl Compr Cane Netw ,2010,8 :740-801.
  • 2Orelli B, McClendon TB, Tsodikov OV , et a1. The XPA -binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. JBe ,2010 ,285 :3705-3712.
  • 3Vilmar AC; Rugiu ES, S<t>rensen JB. ERCC1 and histopathology in ad?vanced NSCLC patients randomized in a large multicenter phase III tri?al. Annals of Oncology ,2010,21 : 1817-1824.
  • 4Ren SX,Zhou SW ,Zhang L,et al. High-Level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced non-small cell lung cancer patients. Cancer Investigation, 2010 ,28 : 1078 -1 083.
  • 5Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small?cell lung cancer: a systematic review and meta-analysis. Clinical Lung Cancer ,2011 ,12 :393401.
  • 6Chang IY, Kim MH. Small interfering RNA-induced suppression of ER?CC 1 enhances sensitivity of human cancer cells to cisplatin. Biochemical and Biophysical Research Communications, 2005 ,327 : 225 -233.
  • 7Tomoyoshi T, Tokujiro Y, Chikako, K. Effects of excision repair cross- complementation group 1 ( ERCC1 ) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer, 2010,67 : 101-107.
  • 8Isla D, Sarries e, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology, 2004 ? 15 : 1194 -1203.
  • 9Yin M, Yan JR, Voutsina A, et a1. No evidence of an association of ER?eCI and ERCC2 polymorphisms with clinical outcomes of platinum?based chemotherapies in non-small cell lung cancer: A meta-analysis. Lung Cancer ,2011,72 :370-377.
  • 10Ish MT, Choi YD, Cho HJ, et al. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype. Respirology ,2012,17 : 127 -133.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部